Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice

Invasive group A streptococcal infections

Erica Weir and Cheryl Main
CMAJ July 04, 2006 175 (1) 32; DOI: https://doi.org/10.1503/cmaj.060241
Erica Weir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Main
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Background and epidemiology: Streptococcus pyogenes is a ubiquitous bacterial organism that gives rise to a wide variety of cutaneous and systemic infections (Fig. 1). It is an important cause of acute pharyngitis and can lead to the development of scarlet fever and nonsuppurative sequelae such as rheumatic heart disease and glomerularnephritis.1 S. pyogenes primarily comes to the attention of public health officials when it manifests as invasive group A streptococci (GAS) infection. This occurs when GAS are isolated either from a normally sterile site or from a nonsterile site and there is evidence of clinical severity: toxic shock syndrome, necrotizing fasciitis (“flesh-eating disease”) or meningitis.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 1: Strep throat, caused by group A Streptococcus (GAS). Note the inflammation of the oropharynx and petechiae. GAS bacteria are spread through direct contact with mucus from the nose or throat of persons who are infected, or through contact with infected sores or skin wounds. Photo by: CDC/Heinz F. Eichenwald

In 2000, Health Canada added invasive GAS infection to the list of reportable diseases. The estimated incidence of these infections for that year was 1.95/100 000 — still relatively rare, although the incidence appeared to be increasing.

Susceptibility to invasive GAS infection appears to depend on a combination of agent and host factors (Box 1). The bacteria produces a number of exotoxins and proteins, including M protein, an important virulence determinant. Strains rich in M protein are resistant to phagocytosis, multiply rapidly in human blood and are capable of initiating disease. GAS may be divided into serotypes according to antigenic differences in the M protein and, more recently, into genotypes on the basis of nucleotide differences in the emm gene encoding the molecule. More than 150 different M-protein gene sequences types (emm types) have been documented, rendering the emm type an important surveillance tool in investigations of the dynamics of GAS disease.2

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

Clinical management: Necrotizing fasciitis is an infection of the subcutaneous tissues and fascia characterized by extensive and rapidly spreading necrosis. It may start innocently and should be suspected when the patient's pain is out of proportion to the clinical findings. The area of cellulitis often progresses rapidly and may look necrotic. Management requires prompt recognition, surgical débridement, high-dose intravenous penicillin, and clindamycin to reduce toxin (protein) synthesis by the organism.1

Toxic shock syndrome is diagnosed when hypotension coexists with signs of 2 or more of adult respiratory distress syndrome, coagulopathy, liver dysfunction, a generalized maculopapular rash, renal impairment and soft-tissue necrosis. Treatment amounts to penicillin, clindamycin and immune globulin (all delivered intravenously) with intensive supportive care.1

Prevention: No vaccine currently exists that will prevent GAS infections. Patients admitted to hospital should undergo droplet precautions for the first 24 hours of antibiotic therapy.

Although such patients' close contacts are conventionally administered prophylactic antibiotics, a recent review of evidence3 suggests that this convention may be based more on tradition than evidence. We recommend instead that prophylaxis be administered to contacts with risk factors for sporadic disease (Box 1) and their household members. Patient contacts without risk factors should, instead of receiving antibiotics automatically, be educated about the clinical manifestations of GAS infections and maintain a heightened index of suspicion for 30 days after the diagnosis of the index case.

Oral penicillin is the prophylactic antibiotic of choice. Azithromycin is indicated for patients who are allergic to penicillin, provided that the bacterial strain isolated in the index case demonstrates susceptibility to it.3

REFERENCES

  1. 1.↵
    Bisno A, Stevens D. Streptococcus pyogenes. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infections diseases, vol. 2. 6th ed. New York: Churchill Livingstone; 2005. p. 2362-79.
  2. 2.↵
    Ekelund K, Darenberg J, Norrby-Teglund A, et al. Variations in emm type among group A streptococcal isolates causing invasive or non-invasive infections in a nationwide survey. J Clin Microbiol2005;43:3101-9.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    Smith A, Lamagni T, Oliver I, et al. Invasive group A streptococcal disease: Should close contacts routinely receive antibiotic prophylaxis? Lancet Infect Dis 2005;5:494-500.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 175 (1)
CMAJ
Vol. 175, Issue 1
4 Jul 2006
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (p 109-116)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Invasive group A streptococcal infections
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Invasive group A streptococcal infections
Erica Weir, Cheryl Main
CMAJ Jul 2006, 175 (1) 32; DOI: 10.1503/cmaj.060241

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Invasive group A streptococcal infections
Erica Weir, Cheryl Main
CMAJ Jul 2006, 175 (1) 32; DOI: 10.1503/cmaj.060241
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

Collections

  • Topics
    • Dermatology
    • Infectious diseases

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire